Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B
نویسندگان
چکیده
منابع مشابه
Anti-CD20 antibody therapy for B-cell lymphomas.
n engl j med 366;21 nejm.org may 24, 2012 2008 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented...
متن کاملAnti - a Anti - B Anti - a , B
Blood group antigens are structural variants in surface carbohydrate or amino acid polymorphisms on extracellular domains of membrane proteins. The red cell water channelforming integral protein (Aquaporin CHIP) is a homotetramer with only one N-glycosylated subunit, however no CHIP-associated blood group antigens have yet been identified. Immunoblotting, monosaccharide composition analysis, an...
متن کاملOfatumumab: a novel monoclonal anti-CD20 antibody
Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC). Pha...
متن کاملAnti-CD20: tales of identical twins?
atomic resolution structural information is X-ray crystallography, a technique accounting for 88% of structures deposited in the Protein Data Bank. Unfortunately, this technique requires milligram amounts of purified protein , which has to subsequently be induced to form crystals. Both protein production and crystallization can be difficult tasks particularly for membrane-bound, multidomain and...
متن کاملPerspectives Am“B”valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis
Accumulating evidence has designated B cells as central players in the pathogenesis of immune diseases. In the late 1990s, anti-CD20 monoclonal antibodies were developed for the treatment of B-cell nonHodgkin lymphomas, offering the opportunity to efficiently deplete the B-cell compartment for therapeutic immunointerventions. Several studies have since established the beneficial effect of this ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista médica de Chile
سال: 2011
ISSN: 0034-9887
DOI: 10.4067/s0034-98872011000300012